Based on unprecedented advances in our understanding of the pathogenesis of this disease during the last 20 years and the development of derived innovative therapeutics such as Immunomodulatory Drugs (IMiDs), proteasome inhibitors, CD38- and CS1/SLAMF7-targeted monoclonal antibodies, B cell maturation antigen (BCMA)-targeted therapies, and the Exportin-1 (XPO-1) inhibitor selinexor, survival rates in MM patients have increased significantly, approaching a median overall survival (mOS) of 10 years. This evidence concerns the gene TNFRSF17 and Miyoshi myopathy.